Skip to main content
    X

    Xenon Pharmaceuticals Inc (XENE)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $38.78
    -0.48 (-1.22%)

    Market Cap: $3.98B

    Last updated: Nov 17, 2026 at 4:40 PM ET

    Xenon Pharmaceuticals Inc (XENE) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Xenon Pharmaceuticals (XENE) has a market cap of $3.98B and an enterprise value of $3.90B. Its share count is up 25.89% from a year earlier. Revenue fell 100.00% over the last 12 months from the 12 months before.

    Total Valuation

    Enterprise value is 2.08% below the market cap, as cash exceeds debt.

    Market Cap$3.98B
    Enterprise Value$3.90B
    Latest price (Nov 17, 2026)$38.78

    Key Dates

    The next earnings report is expected on Feb 24, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateFeb 24, 2027 (expected)
    Last Earnings DateNov 9, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 0.16% in the quarter ended Sep 30, 2026 and grew 13.15% a year over 2 years.

    Shares Outstanding99.77M
    Shares Change (YoY)+25.89%
    Shares Change (QoQ)+0.16%
    Share Count Growth (2Y CAGR)+13.15%

    Price Statistics

    The stock is down 4.86% over 52 weeks and trades 3.77% below its 50-day average.

    Beta (1Y)0.80
    52-Week Change-4.86%
    1-Month Change+10.55%
    3-Month Change-37.77%
    6-Month Change-28.25%
    5-Year Change+20.10%
    10-Year Change+392.24%
    Total Return (1Y)-4.86%
    Total Return (3Y CAGR)+9.62%
    Total Return (5Y CAGR)+5.78%
    Return vs SPY (1Y)-16.07%
    Max Drawdown (1Y)-52.80%
    Max Drawdown (3Y)-52.80%
    Sharpe Ratio (1Y)-0.07
    Correlation with SPY (1Y)0.17
    50-Day Average$40.30
    200-Day Average$52.25
    52-Week Range$33.38 to $72.66
    RSI (14 Days)47.7
    Average Volume (20 Days)1.35M

    The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 21.19x current liabilities, and total debt is 0.00x shareholder equity.

    Current Ratio21.19x
    Quick Ratio21.19x
    Debt / Equity0.00x

    Returns and Efficiency

    Return on equity is -37.40% over the last 12 months, against a 5-year average of -28.37%.

    Return on Equity (ROE)-37.40%
    Return on Assets (ROA)-35.73%
    ROE (5Y Average)-28.37%
    ROA (5Y Average)-26.66%
    ROIC (5Y Average)-63.90%

    Scores

    XENE has a Piotroski F-Score of 1 of 9, in the weak band of 0 to 2.

    Piotroski F-Score1 of 9
    Piotroski StrengthWeak

    Income Statement

    Revenue was $0 over the last 12 months.

    Revenue$0
    Revenue Growth (YoY)-100.00%
    Gross Profit-$611.00K
    Operating Income-$465.32M
    Pretax Income-$429.51M
    Net Income-$428.73M
    Reported EPS (TTM)-$4.70

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 95.83% of the $1.20B in total assets.

    Cash and Equivalents$82.56M
    Total Debt$0
    Net Cash$82.56M
    Net Cash Per Share$0.83
    Working Capital$914.76M
    Shareholder Equity$1.15B
    Book Value Per Share$11.49
    Total Assets$1.20B
    Total Liabilities$53.49M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After $1.01M of capital spending, operating cash flow left -$357.11M of free cash flow.

    Operating Cash Flow-$356.10M
    Capital Expenditures$1.01M
    Free Cash Flow-$357.11M
    FCF Per Share-$3.69
    Depreciation and Amortization$2.32M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Growth

    Revenue fell 7.36% a year over 3 years.

    Revenue Growth (3Y CAGR)-7.36%
    Revenue Growth (5Y CAGR)-25.26%
    Book Value Per Share Growth (2Y CAGR)-25.60%
    Tangible Book Per Share Growth (2Y CAGR)-25.60%

    Revenue and profit by year

    Dividends and Yields

    XENE does not pay a dividend. Its free cash flow yield is -9.23%.

    FCF Yield-9.23%
    Buyback Yield-21.65%
    Shareholder Yield-21.65%

    Analyst Forecast

    Consensus estimates put revenue growth at 92.59% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)+92.59%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Frequently Asked Questions About XENE

    What is XENE's market cap?

    Xenon Pharmaceuticals has a market cap of $3.98B. Its enterprise value, which adds debt and subtracts cash, is $3.90B.

    How many shares of XENE are outstanding?

    Xenon Pharmaceuticals has 99.77M shares outstanding. The count is up 25.89% from a year earlier.

    Does XENE pay a dividend?

    No. Xenon Pharmaceuticals does not pay a dividend.

    How much debt does XENE have?

    Xenon Pharmaceuticals has $0 of total debt and $82.56M of cash and equivalents, a net cash position of $82.56M.